Abstract: To evaluated the efficacy and safety of the postoperative adjuvant FCF chemotherapy for patients with colorectal carcinoma (Dukes B). Methods: A total of 102 patients with Dukes B stage bowel carcinoma, who had undergone curative resection alone (CRA group) or received FCF- based postoperative adjuvant chemotherapy(FCF group), were reviewed. The end- point was 5- year survival rate and 3- year disease- free survival rate. The side effects were recorded. Results: After a median follow- up of 41 months, The rate of 3- year disease- free survival was 80.0%and 62.5%(P=0.019) respectively for the FCF group and CRA group. The 5- year survival rate for patients with Dukes B stage colorectal carcinoma in each group was 89.97% and 66.73%(P<0.05) respectively for the FCF group and CRA group. The main side effects include anorexia, nausea/vomiting, alopecia and pigmentation. Most of the side effects were tolerable and mild. Conclusion: Postoperative adjuvant FCF chemotherapy improves 3- year disease- free survival rate and the 5- year survival rate of the patients with Dukes B stage colorectal carcinoma. The regimens of FCF are tolerant and safe.